COMPLETEDPHASE3

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT01830140•Allergan

View on ClinicalTrials.gov

Summary

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of glaucoma or ocular hypertension

Exclusion Criteria

•Active ocular disease other than glaucoma or ocular hypertension
•Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)

Locations (2)

Artesia, California, United States

El Paso, Texas, United States

Key Dates

Start Date

July 1, 2013

Primary Completion Date

May 1, 2014

Completion Date

May 1, 2014

Last Updated

May 6, 2015

Enrollment

466

ACTUAL participants

Conditions

GlaucomaOcular Hypertension

Interventions

Bimatoprost 0.01%

DRUG

Bimatoprost 0.03%

DRUG

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545

GlaucomaOcular Surface Disease

View study

RECRUITINGNA

Automated Applanation Tonometry - Updated

NCT07298356

GlaucomaGlaucoma, Suspect

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 6, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE4